1 / 4

A Novel Treatment For Triple-negative Breast Cancer

Recently, the team of Professor Jin Hongjun from the Molecular Imaging Center of Sun Yat-sen University No.5 Hospital and the Tumor Center of Sun Yat-sen University No.5 Hospital explored a novel method to improve hypoxia in photodynamicu00a0therapy, and preliminarily found that oxyphotodynamic therapy combined withu00a0metforminu00a0has the potential to treat triple-negative breast cancer.

Download Presentation

A Novel Treatment For Triple-negative Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Huateng Pharma A Novel Treatment For Triple-negative Breast Cancer https://en.huatengsci.com Triple-negative breast cancer is a cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. These results mean the growth of the cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. So, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2 protein receptors. This type of breast cancer accounts for 10-20% of all types of breast cancer. It has special biological behavior and clinicopathological characteristics, and the prognosis is worse than other types. For doctors and researchers, there is intense interest in finding new medications that can treat this kind of breast cancer. Photodynamic therapy is a novel method for the treatment of breast cancer. By combining a photosensitizer with a corresponding light source, reactive oxygen species (ROS) are generated to selectively destroy the diseased tissues, so as to kill the cancer cells. But at the same time it will also lead to the formation of hypoxia in tumor tissues and reduce the therapeutic effect. Recently, the team of Professor Jin Hongjun from the Molecular Imaging Center of Sun Yat-sen University No.5 Hospital and the Tumor Center of Sun Yat-sen University No.5 Hospital explored a novel method to improve hypoxia in photodynamic therapy, and

  2. Huateng Pharma preliminarily found that oxyphotodynamic therapy combined with metformin has the potential to treat triple-negative breast cancer. The research was published in the Annals of Translational Medicine (ATM,IF:3.297). https://en.huatengsci.com Hypoxia occurs during photodynamic therapy, and there is no effective treatment method. At present, a large amount of research is focused on the improvement of light sources and the development of third-generation nanomaterials. This research aims to solve the problem of photodynamic hypoxia from the perspective of photodynamic therapy equipment, transport the pure oxygen produced by physical oxygen production technology to a specially designed irradiator integrated with gas, light and electricity. Oxygen and light irradiation work synchronously in the treatment area to maintain stable oxygen-enriched state in the local area and avoid the toxic and side effects of nanomaterials. The advantages of oxyphotodynamic therapy versus photodynamic therapy in triple negative breast cancer were first explored. Aminolevulinic acid (ALA) mediated photodynamic (PDT) and oxyphotodynamic (OPDT) were used to treat triple-negative breast cancer cells MDA-MB-231 cells, and the 50% inhibitory concentrations (IC50) were calculated to be 10.62±1.22 mM 和 7.71±1.26 mM. Compared with ordinary photodynamic therapy, oxyphotodynamic therapy has obvious advantages in inhibiting the growth of cancer cells.

  3. Huateng Pharma https://en.huatengsci.com ▲The inhibitory effect of ALA (A), ALa-PDT (B) and ALa-OPDT (C) on MDA-MB-231 cells at different concentrations, and the cell survival rate (D) of the above three groups at different concentrations of ALA were compared with that of the control group (0 mM).*, P < 0.05;* *, P < 0.01;* * *, P < 0.001. At the same time, Professor Jin Hongjun’s team also found that metformin and 5-aminolevulinic acid (ALA)-mediated oxyphotodynamic therapy have a synergistic effect in the treatment of tumors. The combined use of the two at different concentrations can be calculated by CompuSyn software. It is concluded that the combination index (CI) is <1. Under the confocal microscope, it can be seen that the expression of protoporphyrin IX (PpIX) in the oxyphotodynamic therapy group has increased, confirming the enhancement of the therapeutic effect. With the progress of oxyphotodynamic therapy, the supply of oxygen can increase the generation of oxygen free radicals or singlet oxygen. And ultimately lead to the death of tumor cells. ▲Micromirror analysis showed that metformin had the most significant therapeutic effect when it was treated with ALA and oxyphotodynamic. (A, D, G, J) Protoporphyrin IX (PpIX); (B, E, H, K) Mitochondrial

  4. Huateng Pharma https://en.huatengsci.com green fluorescent protein (MTG); (C, F, I, L) Protoporphyrin IX (PpIX) + mitochondrial green fluorescent protein (MTG). The transmitting wavelength of PpIX was 610±20 nm and MTG 530±30 nm. Therefore, researchers believe that oxyphotodynamic therapy can alleviate the hypoxia problem in photodynamic therapy through physical oxygen supply. Combined with metformin is a potential new method for the treatment of triple-negative breast cancer, but the specific mechanism needs further research. This study provides a preliminary basis for further research on the role of metformin combined with oxyphotodynamic therapy in the treatment of recurrent or metastatic triple-negative breast cancer. Huateng Pharma is a world leading supplier of PEG derivatives and a professional manufacturer of wide series of APIs, pharmaceutical intermediates and research chemicals. We provide anti-cancer intermediate products, such as Palbociclib and Ribociclib which used for the treatment of certain kinds of breast cancer. We are committed to providing cost-effective pharmaceutical products and services to customers worldwide with the belief of “Strive for the Human Health". Reference: [1] Pei X, Wang X, Xian J, Mi J, Gao J, Li X, et al. Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer. Annals of Translational Medicine. 2020;8:1138-.

More Related